title: [Drug surveillance note. Telangiectasis and calcium antagonists].
authors.affiliation: Service de Dermatologie, Hôpital Fournier, Nancy.
authors.forename: J L
authors.initials: JL
authors.lastname: Schmutz
authors.forename: A
authors.initials: A
authors.lastname: Barbaud
authors.forename: P
authors.initials: P
authors.lastname: Tréchot
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D015736:Felodipine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage*; D011358:Product Surveillance, Postmarketing; D013684:Telangiectasis / Q000139:chemically induced*
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017311:Amlodipine; D009543:Nifedipine; D015736:Felodipine